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Hereditary haemorrhagic 
telangiectasia in North African 
and sub-Saharan patients
To the Editor: Hereditary haemorrhagic telangiectasia (HHT) or 
Osler-Weber-Rendu disease is an autosomal-dominant inherited 
vascular disease, characterised by the presence of mucocutaneous 
telangiectasia and visceral arteriovenous malformations (AVMs). 
Three main causative genes are known: ENG, ACVRL1 and SMAD4. 
BMP9 has also been shown to be involved in a small number of 
cases. We report two cases of HHT in North African and sub-
Saharan patients.
HHT is a vascular dysplasia that affects approximately 1 in 5 000 - 
8 000 individuals,[1] with regional differences due to founder effects. [2,3] 
The clinical diagnosis of HHT is based on the Curaçao criteria,[1] 
including: spontaneous and recurrent nosebleeds; mucocutaneous 
telangiectasia at characteristic sites (nose, lips, oral cavity, fingertips 
and gastrointestinal mucosa); AVMs in lungs, liver, gastrointestinal 
tract, brain and spinal cord; and a first-degree relative with HHT. 
Approximately 85% of HHT patients[3] have a mutation identified in 
either ENG (OMIM#187300, HHT1)[4] or ACVRL1 (OMIM#600376, 
HHT2);[5] and 2% of the HHT families have a mutation identified 
in the SMAD4 gene, present in HHT in association with juvenile 
polyposis (OMIM #175050, JPHT).[6]
For both ENG and ACVRL1, many mutations have been reported 
by independent groups in different countries, in most cases without 
any evidence of a founder effect, which could be suspected only in 
a limited number of cases.[2,7] As is known, HHT in people of black 
African descent is a rarity. To date, only one paper reports a mutation 
(exon 7 of ACVRL1: c.818T>C, p.L273P) in an HHT black adult 
patient born in Kenya,[8] as Westermann et al.[9] discuss in their letter. 
The other cases in literature were published before the identification 
of the two disease-related genes.[2] A December 2012 census showed 
that the number of immigrants from North Africa and sub-Saharan 
countries, residing regularly in Italy, for whom the public healthcare 
service is fully available, is 760  500 and 350  000, respectively. 
However, a high number of non-registered immigrants are certainly 
10
9
8
7
6
5
4
3
2
1
SCORE
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
| 10 | 20 | 30 | 40 | 50 | 60 | 80 | 90 | 100 | 110
| 10 | 20 | 30 | 40 | 50 | 80 | 90 | 100 | 110
A
B
YB-1
SF2/ASF
SRp40
ETR-3
ETR-3
ETR-3 ETR-3
ETR-3
SRp40
SRp30c
Sam68
SRp30c
Sam68
SRp40
SF2/ASF
SRp40
0c
ETR-3
ETR-3
ETR-3
1
ETR-3
ETR-3
YB-1
1
hnRNP P  (TLS)
hnRNP A1
Fox-1
Fox-2
CUG-BP1
CUG-BP1
CUG-BP1
TDP43
TDP43
TDP43
(PTB)
(PTB)
hnRNP P  (TLS)
hnRNP DL
hnRNP A1
CUG-BP1
CUG-BP1
CUG-BP1
TDP43
TDP43
TDP43
hnRNP I (PTB)
(PTB)
CUG-BP1
Fox-1
Fox-2
hnRNP I
hnRNP I
hnRNP I
CUG-BP1
CUG-BP1
CUG-BP1
CUG-BP1
CUG-BP1
CUG-BP1
CUG-BP1
CUG-BP1
CUG-BP1
CUG-BP1hnRNP DL
SRp3
Nova-
Nova-1
Nova-1
SRp30c
Nova-1
Nova-1
Nova-1 Nova-1
hnRNP H1
hnRNP H2
ggguggcacaaccuauacaaaucugacuggacugugugugucucuccucugugucccccacGGCCCGUCACAGCUGGAGCUGACUCUCCAGGCAUCCAAGCAAAAUGGCACCUGGCCC
| 60 | 70
SRp40
Nova-
ggguggcacaaccuauacaaaucugacuggacugugugugucucuccucugugucccccagGGCCCGUUACAGCUGGAGCUGACUCUCCAGGCAUCCAAGCAAAAUGGCACCUGCCC
| 70
CUG-BP1
hnRNP H3
10
9
8
7
6
5
4
3
2
1
SCORE
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
ETR-3
CUG-BP1
hnRNP F
ETR-3
Fig. 1. SpliceAid analysis of ENG mutation (c. 220-1G>C, splice defect). (A) hnRNP exonic splicing silencer (ESS) in wild-type sequence of intron2/exon3 of 
ENG (circled); (B) SRp40 exonic splicing enhancer (ESE) in mutated sequence of intron2/exon3 of ENG (circled).
CORRESPONDENCE
257       April 2014, Vol. 104, No. 4
present. The countries of origin of the two patients are those with the 
highest number of immigrants to Italy from North African or sub-
Saharan areas – Morocco and Senegal. 
We wish to report our observation on two patients among the ~500 
index cases, collected by the centres caring for HHT in northern Italy, 
in Pavia and Crema. The HHT diagnosis was arrived at according to 
Curaçao criteria. The first case is a patient born in Morocco (regular 
immigrants: ~501  600) with a ‘possible’ diagnosis of HHT (2/4 
Curaçao criteria). The second patient was born in Senegal (regular 
immigrants: ~81 000) with a ‘definite’ diagnosis of HHT (3/4 Curaçao 
criteria).
Molecular analysis of ENG and ACVRL1, according to Olivieri et 
al.,[10] disclosed a mutation in intron 2 of ENG (c.220-1G>C, splice 
defect) and a mutation in exon 8 of ACVRL1 (c.1232G>A, p.R411Q), 
respectively. Analysis of exon 3 of ENG, including intron-exon 
boundaries, covers 20% of the mutations identified in this gene 
in our lab. The mutation observed is yet unpublished. Analysis 
of splice sites with SpliceAid (http://www.introni.it/) (Fig.  1) and 
Human Splicing Finder (http://www.umd.be/HSF/), bioinformatics 
tools useful for predicting the effect of splicing mutations, shows 
the replacement of an exonic splicing silencer (ESS) with an exonic 
splicing enhancer (ESE). Overall, bioinformatics tests suggest 
that the mutation is pathogenetic. Exon 8 of the ACVRL1 gene 
carries 24% of the mutations identified in this gene in our lab. We 
observed the same mutation in 5/38 index cases from unrelated 
families and it has also been reported several times in the HHT 
mutation database (http://arup.utah.edu/database/hht/) in patients 
from different ethnic origins. 
Overall, these data support the observation by Westermann et al.[9] 
regarding the rarity of HHT in patients from Africa. We are aware of 
the limitations associated with reporting single cases, but we feel a 
short report of this observation is relevant as data are totally lacking 
regarding the incidence and prevalence of HHT, and the relative 
involvement of ENG or ACVRL1 in the African population.
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Physician, heal thyself: Creative writing 
as a tool for self-care and enhancing 
care of others
 I was afraid that … conforming to the modes of behaviour expected 
of a doctor would distort my sense of self and my passion for art.
 – AS (second-year medical student)
To the Editor: In his recent article in the SAMJ,[1] Prof. Steve Reid 
questions whether inclusion of art and humanities in the medical 
curriculum can improve the flexibility and skill of a graduate. 
As a writer and a general practitioner, I have struggled with the 
split between my artistic life and that of working with the ill, the 
injured and the emotionally hurt. As a student, I developed a chronic 
condition; although medication helped limit morbidity, it was my 
practise of taking emotional difficulty to the page that helped me 
manage stressors that adversely impacted on my health. 
Wishing to pass on tools that helped me look after myself, I run 
workshops in memoir writing, and wrote a book titled Eloquent 
Body.[2] Recently, I was invited to mentor four medical students in a 
writing project. 
Since 2011, Prof. Reid has offered groups of second-year University 
of Cape Town medical students the option to research the relationship 
between art and medicine during a one-month special studies 
module (SSM). An accomplished musician, Prof. Reid knows the 
life-enhancing benefits of artistic practice, and was concerned that 
medicine excluded this valuable component of health.
The four components of the ‘writing and health’ SSM were: self-
exploration through writing; noticing how language and the patient’s 
narrative are controlled in medical settings; a literature search on 
creative writing and its effects on health; and a visit to hospitalised 
patients, comparing strengths and weaknesses of medical history-
taking with an open-ended conversation where patients used their 
own language to frame their experience. 
Scientists use objective measurement to determine what constitutes 
illness, and which interventions are effective. Most artists work 
intuitively from a subjective space, distilling the essence of experience 
that reflects on the human condition. 
The students wrote:
AS:  ‘I thought I would be told what to do, as in the rest of medical 
studies. I didn’t realise that I would have to find my own way, 
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